- Home
- FIEE vs ALGS Comparison
FIEE vs ALGS Comparison
Compare FIEE & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FIEE | ALGS |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | 43 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.6M | 43.0M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | FIEE | ALGS |
|---|---|---|
| Price | $7.00 | $6.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $47.00 |
| AVG Volume (30 Days) | 18.2K | ★ 34.3K |
| Earning Date | N/A | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,186,000.00 |
| Revenue This Year | N/A | $4.99 |
| Revenue Next Year | N/A | $8.89 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.50 | $3.76 |
| 52 Week High | $7.95 | $13.69 |
Technical Indicators
Market Signals| Indicator | FIEE | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 53.14 | 42.07 |
| Support Level | $6.60 | $6.21 |
| Resistance Level | $7.26 | $8.42 |
| Average True Range (ATR) | 0.34 | 0.51 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 27.02 | 3.23 |
Price Performance
Historical ComparisonAbout FIEE FiEE Inc
FiEE Inc, formerly Minim Inc is a digital service provider focused on integrating artificial intelligence and data analytics into content creation and brand management. The company offers a range of services designed to support creators, artists, and businesses in developing, managing, and optimizing their digital presence across various platforms, including customized graphic and posts, short videos, and editorial calendars aligned with brand goals.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.